莫塞替諾特
莫塞替諾特 | |
---|---|
IUPAC名 N-(2-Aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide | |
識別 | |
CAS號 | 726169-73-9 |
PubChem | 9865515 |
ChemSpider | 8041206 |
SMILES |
|
InChI |
|
InChIKey | HRNLUBSXIHFDHP-UHFFFAOYAW |
ChEBI | 197437 |
KEGG | D09641 |
IUPHAR配體 | 7008 |
性質 | |
化學式 | C23H20N6O |
摩爾質量 | 396.44 g·mol−1 |
若非註明,所有數據均出自標準狀態(25 ℃,100 kPa)下。 |
莫塞替諾特(英語:Mocetinostat,開發代號:MGCD0103)是一種含氮有機化合物,分子式C23H20N6O,屬於苯甲酰胺類組織蛋白去乙醯酶抑制劑。[1][2][3]
參考文獻
- ^ Pharmion Corporation (PHRM) Release: Clinical Data On Oncology HDAC Inhibitor MGCD0103, Presented At The American Society of Clinical Oncology 42nd Annual Meeting (新聞稿). Colorado, United States: BioSpace. June 6, 2006. (原始內容存檔於July 16, 2011).
- ^ Gelmon, K.; Tolcher, A.; Carducci, M.; Reid, G. K.; Li, Z.; Kalita, A.; Callejas, V.; Longstreth, J.; Besterman, J. M.; Siu, L. L. Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors. J. Clin. Oncol. 2005, 23 (16S). 3147. (原始內容存檔於2012-07-11).
- ^ MethylGene to Resume Development of its HDAC Inhibitor, MGCD0103 (Mocetinostat), Sept 2009